Physician profile
Laura Young
NPI 1710968698
$4,161.42
in general payments reported to CMS, 2019-2025
12 companies · $623 in 2025
The $623 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $252 · 2021: $826 · 2022: $662 · 2023: $760 · 2024: $638 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704 · Entertainment: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.60 |
| Entertainment | $317.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $826.32 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $795.78 | 2021-2025 | Total30, Precision7, Dailies Total1 |
| Coopervision INC. | $622.06 | 2020-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Optos, INC. | $472.95 | 2022-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Maculogix, INC. | $340.59 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $301.16 | 2022-2024 | Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $242.47 | 2019-2020 | |
| Sight Sciences, INC. | $164.62 | 2022 | |
| Lkc Technologies, INC. | $158.31 | 2024 | |
| Astellas Pharma US INC | $130.65 | 2025 | Izervay |
| Allergan, INC. | $84.00 | 2020 | |
| Horizon Therapeutics Plc | $22.51 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.